drugset / Trial / NCT07099274
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/ CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable intermediate-to-advanced hepatocellular carcinoma.
Timeline
- Start
- 2025-08-22
- Primary completion
- 2027-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tuvonralimab | Monoclonal antibody | 7.5 mg/kg | — |
| Background | Lenvatinib | Small molecule | 8 mg | Oral |
| Background | Lenvatinib | Small molecule | 12 mg | Oral |